


# **New genetic technologies for non-invasive detection of Down syndrome**

Helen White, PhD

Senior Scientist



National Genetics Reference Lab (Wessex)

# Outline of talk



- Cell free fetal nucleic acids in blood of pregnant women
  - how can they be used for DS testing?
  
- New non-invasive techniques for detection of DS
  - ❖ Quantitative SNP analysis from cffRNA
  - ❖ Digital PCR of cfDNA and cffRNA
  - ❖ Shot gun sequencing of cfDNA

# Current prenatal diagnosis requires invasive procedures





**1% risk of miscarriage**

**Not possible before 11 weeks' gestation**

# Other sources of fetal tissue for non-invasive prenatal diagnosis

## Fetal cells in maternal circulation

erythroblasts  
trophoblastic cells  
leucocytes



Difficult to isolate and persist for years after pregnancy

## Cell free fetal nucleic acid in the maternal circulation

Detectable from 5 weeks' gestation

Cell free fetal DNA: 3 - 6% of total circulating cell free DNA  
94 - 97% of cell free DNA is maternal

Cell free fetal RNA: fetal specific transcripts identified


Both DNA and RNA cleared from circulation within 30 minutes of delivery

Originates from trophoblast

NHS

NGRL WESSEX

# Extraction of cell free fetal nucleic acids from maternal plasma



 Cell free maternal DNA (96.6%)

 Cell free fetal DNA (3.4%)

Amount of cf fetal DNA extracted is equivalent to 25 genomes / ml plasma

 Cell free maternal RNA

 Cell free fetal RNA

# How can cell free fetal nucleic acids be used for non-invasive Down syndrome testing?

- **Major technical challenge**

Background of cell free maternal **DNA** means direct quantification of fetal chromosome copy number is problematic and technically demanding

Ideally need:

targets that are free from maternal background interference

and / or

technologies that enable extremely accurate copy number 'counting'


- **Recent major breakthroughs**

Quantitative analysis of Single Nucleotide Polymorphisms in **fetal specific** mRNAs

Digital PCR of cfRNA and cfDNA

Shotgun sequencing of cfDNA


NHS




NGRL WESSEX

# Quantitative analysis of Single Nucleotide Polymorphisms in fetal specific mRNAs

# Quantitative analysis of SNPs in fetal specific mRNA





# Quantitative analysis of SNPs in fetal specific mRNA



# Quantitative analysis of SNPs in fetal specific mRNA


## Analysis by MALDI-TOF (mass spectrometry)

- PLAC4 mRNA (  ) is derived exclusively from fetal chromosome 21
- PLAC4 mRNA expressed in the placenta and is found in the plasma of pregnant women



# Quantitative analysis of SNPs in fetal specific mRNA

## Analysis by MALDI-TOF (mass spectrometry)



- Correctly diagnosed fetal trisomy 21 in **90%** of +21 cases (n=10)

- Excluded diagnosis of trisomy 21 in **96.5%** of normal controls (n=57)

- **Sensitivity: 90%**

- **Specificity: 96.5%**

# Quantitative analysis of SNPs in fetal specific mRNA

## ▪ ADVANTAGES

- Diagnostic sensitivity and specificity using one marker are comparable to multiple marker screening tests for DS currently in practice (if informative)
- Test is insensitive to gestational age and can be offered early in pregnancy
- Target free of maternal background

## ▪ DISADVANTAGES


- Fetus has to be informative for SNP analysed
  - testing of the PLAC4 SNP will only give a result for 40% of pregnant women

## ▪ FUTURE REQUIREMENTS

- Identification of more polymorphic loci to increase informative cases – population dependent
- Multi centre large scale validation required
- Expand testing to include fetal specific transcripts from chromosomes 18 & 13

# Quantitative analysis of SNPs in fetal specific mRNA

## Sequenom Inc, SEQureDx(TM) Technology



- Developed quantitative RNA SNP test analysing multiple (>10) SNPs on chr 21:
  - increases test coverage to **greater than 95%** in the US population
- Complete concordance with clinical results in 619 samples tested to date
- Initiating multi-site 5000-sample laboratory developed test (LDT) validation study
- Acquired Center for Molecular Medicine, a CLIA-certified molecular diagnostics lab and anticipate commercial launch of **primary screening test** in **June 2009**
- Sponsoring RNA Noninvasive Aneuploidies ("RNA") study:
  - multi-center, prospective study involving 10,000 samples from first and second trimester pregnancies using the SEQureDx technology, managed and analysed by an independent third-party
- Identified novel markers for Trisomy 18 that have passed initial selection criteria



NHS

# Digital PCR

Digital RNA SNP strategy

Relative chromosome dosage




NGRl WESSEX


# Quantitative analysis of SNPs in fetal specific mRNA

## Digital PCR

- Dilute cffRNA sample to < 1 copy per reaction well using 384 well plates
- Perform real time PCR for PLAC4 SNP using two coloured probes



- Count red and green wells
- Determine statistically whether an allele is over represented




| Genotype | No. of wells positive for individual alleles |        |     |              | $m_r$ | $P_r$ | SPRT result           |                |
|----------|--|--------|-----|--------------|-------|-------|-----------------------|----------------|
|          | A only                                       | G only | AG  | All negative |       |       | Unclassifiable region | Classification |
| AG       | 90   | 100    | 97  | 97           | 0.67  | 0.526 | 0.62–0.64             | Euploid        |
| AG       | 97   | 105    | 65  | 117          | 0.55  | 0.520 | 0.61–0.63             | Euploid        |
| AG       | 66   | 92     | 34  | 192          | 0.30  | 0.582 | 0.59–0.62             | Euploid        |
| AG       | 29   | 28     | 3   | 324          | 0.08  | 0.509 | 0.54–0.64             | Euploid        |
| AG       | 112  | 85     | 44  | 143          | 0.41  | 0.569 | 0.60–0.62             | Euploid        |
| AG       | 90   | 101    | 72  | 121          | 0.55  | 0.529 | 0.61–0.63             | Euploid        |
| AG       | 73   | 91     | 57  | 163          | 0.41  | 0.555 | 0.60–0.63             | Euploid        |
| AG       | 66   | 90     | 52  | 176          | 0.37  | 0.577 | 0.59–0.62             | Euploid        |
| AG       | 71   | 56     | 17  | 240          | 0.21  | 0.559 | 0.58–0.62             | Euploid        |
| AAG      | 110  | 53     | 21  | 200          | 0.21  | 0.675 | 0.58–0.61             | T21            |
| AAG      | 246  | 127    | 112 | 283          | 0.37  | 0.660 | 0.60–0.61             | T21            |
| AGG      | 66   | 114    | 66  | 138          | 0.42  | 0.633 | 0.60–0.62             | T21            |
| AGG      | 58   | 130    | 54  | 142          | 0.34  | 0.691 | 0.59–0.62             | T21            |


# Can digital PCR be used in a polymorphism independent way?

## PROBLEMS:


- Only 3-6% of the cell- free DNA fraction is fetal
- Expected enrichment of chromosome 21 lies within the range of 1.5% to 3%
- Relative chromosome dosage: can we compare amount of chr 21 present with amount of another autosome?



$$\frac{\text{Total amount of Chr 21 (0.94 + 0.06)}}{\text{Total amount of Chr 9 (0.94 + 0.06)}} = 1$$




$$\frac{\text{Total amount of Chr 21 (0.94 + 0.09)}}{\text{Total amount of Chr 9 (0.94 + 0.06)}} = 1.03$$



## SOLUTIONS:

- Digital PCR provides an alternative method for quantifying the relative abundance of two alleles
- Using existing commercially available microfluidic systems for digital PCR it would be possible to detect T21 if fetal DNA component was 25% (7680 rxns)
- Theroretically it is possible to detect a 1% difference by 'counting' a large number of digital PCR reactions
- Using a prototype "MegaPixel" digital PCR device that allows for 1,000,000 simultaneous single molecule reactions a 3% increase in chromosome 21 has been detected


**ABL gene on C9**



**AIRE gene on C21**



**Tropini and Hansen ISPD poster 2008**



# Digital PCR

## ▪ ADVANTAGES

- Successful proof of principal studies shown have shown utility for quantitative RNA SNP analysis and relative chromosome dosage
- Relative chromosome dosage is polymorphism independent and could be used in all pregnancies


## ▪ DISADVANTAGES

- For RNA SNP analysis the fetus has to be informative for SNP analysed
- At present using relative chromosome dosage can only detect trisomy 21 if fetal DNA component is 25%

## ▪ FUTURE REQUIREMENTS

- For relative chromosome dosage and high throughput RNA SNP analysis higher density digital PCR equipment needs to be developed
- Multi centre large scale validation would be required

**NHS**




**NGRL WESSEX**


# **Shot gun sequencing**

**An alternative method for  
digital quantification of DNA**

# Shotgun sequencing




# Sequencing by Synthesis






**Generate approx 10 million reads** ●



**155,000**

**135,000**

**67,500**




# Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood

H. Christina Fan\*, Yair J. Blumenfeld†, Usha Chitkara‡, Louanne Hudgins‡, and Stephen R. Quake\*§


\*Department of Bioengineering, Stanford University and Howard Hughes Medical Institute, 318 Campus Drive, Clark Center, Room E300, Stanford, CA 94305; †Division of Maternal and Fetal Medicine, Department of Obstetrics and Gynecology, Stanford University, 300 Pasteur Drive, Room HH333, Stanford, CA 94305; and ‡Division of Medical Genetics, Department of Pediatrics, Stanford University, 300 Pasteur Drive, Stanford, CA 94305

Communicated by Leonard A. Herzenberg, Stanford University School of Medicine, Stanford, CA, August 22, 2008 (received for review July 13, 2008)




- Shotgun sequenced plasma DNA samples from 18 pregnant women:
  - 9 trisomy 21
  - 2 trisomy 18
  - 1 trisomy 13
  - 6 normal
- and 1 genomic DNA sample from a male control
- Gestational age 10 – 35 weeks (earliest trisomy case 14 weeks)
- 5 million sequencing reads for each patient
- For each patient compared density of reads on each chromosome to those obtained from a normal genomic DNA sample
- Also compared density of Chr 21 reads from disomy and trisomy 21 samples
- Coverage of Chr 21 sequences in trisomy 21 was 4 – 18% higher than disomic cases

# Results of shotgun sequencing of maternal plasma DNA



# Results of shotgun sequencing of maternal plasma DNA



# Shot gun sequencing

## ▪ ADVANTAGES

- Successful proof of principal study for detection of major trisomies; 13, 18 and 21
- Polymorphism independent and could be used in all pregnancies
- Has potential to detect unbalanced chromosome rearrangements

## ▪ DISADVANTAGES

- Expensive and large amount of data processing – interpretation.
- In current form would not be feasible to adapt to high throughput screening

## ▪ FUTURE REQUIREMENTS

- Technological development required to produce machines and workflow protocols that could cope with a high throughput of samples

# Summary

- New technologies need to be validated in large UK patient cohorts to determine accuracy
- The limits of gestation for testing using all techniques need to be determined
- Laboratory standards need to be developed
  
- Have the potential to replace current Down syndrome screening tests with a test that would be diagnostic
  
- Tests unlikely to replace invasive testing / current screening for some time although Sequenom may offer primary screening / diagnostic test in the US from June 2009
  
- Important to ensure that women and healthcare professionals understand the changes and women fully understand the implications of these tests
  
- NIHR funding secured to evaluate NIPD in more detail and determine the infrastructure and resources that will be required for timely implementation into NHS practice